Abstract
The present study is focused on the first attempt to use an enzymatically produced biological preparation of cyclic diguanosine monophosphate (cyclic di-GMP) for the therapy of animal cancer. Feline breast carcinoma was chosen as the test model. The preparation was administered intratumorally to induce the immunogenic death of a part of the cancer cells and thus carry out the so-called in situ antitumor vaccination. Preliminary results indicate good therapeutic prospects of studied biopreparation for animal cancer treatment.
 In conclusion, the expedience of further trials of cyclic di-GMP preparation for in situ antitumor vaccination was stated. The need to supplement this mono-preparation with another immunostimulating adjuvant characterized by a mechanism of action distinct from that exhibited by cyclic di-GMP was emphasized. DNA preparation comprising the so-called immunostimulating CpG motifs was provided as an example of such compound.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
